CX3CL1 and Parkinson disease: On the other hand, in models of Parkinson’s disease, it was shown that membrane-bound CX3CL1 had no effect on overall disease progression and pathology while sFKN administration significantly improved motor function and preserved TH-positive neurons in the substantia nigra [9, 11].